Despite posting a net loss for the quarter, PROCEPT BioRobotics Corp delivered a first-quarter earnings report that marginally outperformed analyst estimates, while its forward guidance suggests management is eyeing stronger performance later in the year.
Earnings Overview and Key Metrics
For the first quarter of 2026, PROCEPT BIOROBOTICS CORP (NASDAQ:PRCT) reported revenue of $83.1 million, slightly topping the analyst consensus estimate of $82.1 million. The company posted a Non-GAAP net loss per share of -$0.56, which was a penny better than the expected -$0.57.
Despite the slight earnings beat, the company’s bottom line remains under pressure. The net loss for the quarter widened to $31.6 million from $24.7 million in the same period last year, driven by a significant increase in operating expenses. Selling, general, and administrative costs rose to $65.1 million from $55.2 million, while research and development spending increased to $21.5 million.
Key Operational Highlights from Q1 2026:
- System Sales: Sold 49 U.S. Hydros systems (including 2 replacements), with an average selling price of approximately $485,000.
- Procedure Volume: U.S. Aquablation procedures hit approximately 12,200, a robust 30% increase year-over-year.
- Install Base: The U.S. installed base grew to 765 systems, up 40% compared to Q1 2025.
- Gross Margin: Improved to 65%, up from 64% in the prior year and 61% in Q4 2025, driven by favorable revenue mix and pricing.
- Cash Position: The company held approximately $249 million in cash, cash equivalents, and restricted cash as of March 31, 2026.
Market Reaction and Price Action
Investors appear to be focusing on the company’s improved operational discipline and the maintained full-year guidance rather than the modest earnings beat. In after-market trading following the release, PRCT shares surged by 12.85% , signaling a strong positive reaction from the market.
This move comes amid a challenging period for the stock; PRCT had fallen roughly 9.9% over the past month and more than 6% over the last two weeks. The sharp after-market rally suggests that the market was pricing in a worse outcome and is now rewarding the company for its stable outlook and signs of a "reset" in the organization.
Forward Guidance vs. Analyst Estimates
Management reaffirmed its full-year 2026 guidance, which is a critical factor behind the positive market response. The company continues to expect:
- Full-Year Revenue: In the range of $390 million to $410 million
- Full-Year U.S. Procedure Growth: In the range of 39% to 48%
- Full-Year Gross Margin: Approximately 65%
- Full-Year Adjusted EBITDA Loss: Between $30 million and $17 million
For context, analysts are currently estimating full-year 2026 sales at approximately $404.6 million, which falls comfortably within the company's guided range. For the upcoming second quarter of 2026, analysts project sales of roughly $96.7 million. While the company did not provide specific Q2 guidance, the maintained full-year outlook indicates confidence that the business will accelerate as the year progresses.
CEO Larry Wood noted that recent commercial realignment created "some near-term disruption" but that the team is adapting quickly, setting the stage for "sustained growth and improved profitability."
Analyst Views and Innovation Pipeline
The company is also making strides on the technology front. PROCEPT recently received FDA clearance for its second-generation FirstAssist AI software, which enhances the imaging and planning capabilities of the HYDROS robotic system. This advancement strengthens the company’s position in the urology robotics market and supports its long-term growth narrative.
Want to dive deeper into the numbers?
You can view the full historical earnings data, future projections, and detailed analyst estimates for PROCEPT BioRobotics at the following links:
Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Always conduct your own research and consult with a licensed financial advisor before making investment decisions.